Building upon the foundation set in the first edition, Statins: The HMG-CoA Reductase Inhibitors in Perspective examines existing and emerging statins and their beneficial effectiveness in reducing serum cholesterol. The breadth of coverage and depth of information in this book provide an authoritative guide to statins from their discovery through the major clinical trials to the present and explores the future of statin trials and lipid-lowering therapy beyond statins. The book tells the story of statins, for the most part in the words of those who lived it. The major clinical trials from Scandinavia, North America, Australia, New Zealand, and Scotland are detailed by those who conducted them. The book includes information on the pharmacology and mechanisms of action, the statin angiographic trials, the use of statins after vascular surgery, guidelines for the use of the statins in clinical practice, and the cost-effectiveness of statin therapy. New chapters cover combination therapy in lipid-lowering, new 'Megatrials' (HPS and PPP), and the PROSPER study.